Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR1H3 | Q13133 | 20/20 | 1.00 |
| ▸ | NR1H2 | P55055 | 18/20 | 1.00 |
| ▸ | RXRA | P19793 | 2/20 | 0.98 |
| ▸ | MEN1 | O00255 | 1/20 | 0.98 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.98 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.98 |
| ▸ | MAPT | P10636 | 1/20 | 0.98 |
| ▸ | VHL | P40337 | 1/20 | 0.98 |
| ▸ | RECQL | P46063 | 1/20 | 0.98 |
| ▸ | BLM | P54132 | 1/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.98 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL29802701 | 1.00 | NR1H3 (1.00) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| Hydrochloric Acid SCHEMBL29378086 | 1.00 | NR1H3 (1.00) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| SCHEMBL29359875 | 0.99 | NR1H3 (1.00) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| SCHEMBL29383609 | 0.99 | NR1H3 (1.00) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| SCHEMBL2110041 | 0.99 | NR1H3 (1.00) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| SCHEMBL23092274 | 0.97 | NR1H3 (0.95) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| SCHEMBL4951300 | 0.94 | NR1H3 (0.91) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| SCHEMBL13764633 | 0.94 | NR1H3 (0.90) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| Hydrochloric Acid SCHEMBL3980892 | 0.94 | NR1H3 (0.88) | NR1H3NR1H2RXRAMEN1NR1I2 | |
| Hydrochloric Acid SCHEMBL4953139 | 0.93 | NR1H3 (0.87) | NR1H3NR1H2RXRAMEN1NR1I2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118078793-A | Application of GW3965 in preparation of medicine for relieving doxorubicin cardiac injury | 复旦大学附属中山医院 | 2024-05-28 | — | — | CN | claimed |
| EP-3236927-B1 | HAIR COMPOSITION | UNILEVER PLC (GB) | 2019-11-13 | — | — | EP | claimed |
| US-10456344-B2 | Hair composition | CONOPCO, INC. (US) | 2019-10-29 | — | — | US | claimed |
| US-20170360673-A1 | HAIR COMPOSITION | CONOPCO, INC., D/B/A UNILEVER (US) | 2017-12-21 | — | — | US | claimed |
| EP-3236927-A1 | HAIR COMPOSITION | Unilever PLC (GB) | 2017-11-01 | — | — | EP | claimed |
| WO-2016102177-A1 | HAIR COMPOSITION | UNILEVER PLC (GB) | 2016-06-30 | — | — | WO | claimed |
| US-20150031655-A1 | COMBINATION OF LIVER X RECEPTOR MODULATOR AND ESTROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF AGE-RELATED DISEASES | UNIVERSITY OF NORTH DAKOTA (US) | 2015-01-29 | — | — | US | claimed |
| WO-2012142039-A1 | COMBINATION OF LIVER X RECEPTOR MODULATOR AND ESTROGEN RECEPTOR MODULATOR FOR THE TREATMENT OF AGE-RELATED DISEASES | UNIVERSITY OF NORTH DAKOTA (US) | 2012-10-18 | — | — | WO | claimed |
| US-12502368-B2 | Treatment and diagnosis of melanoma | THE ROCKEFELLER UNIVERSITY (US) | 2025-12-23 | — | — | US | disclosed |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20240252458-A1 | TREATMENT AND DIAGNOSIS OF MELANOMA | THE ROCKEFELLER UNIVERSITY | 2024-08-01 | — | — | US | disclosed |
| CN-118078793-A | Application of GW3965 in preparation of medicine for relieving doxorubicin cardiac injury | 复旦大学附属中山医院 | 2024-05-28 | — | — | CN | disclosed |
| US-11865094-B2 | Treatment and diagnosis of melanoma | THE ROCKEFELLER UNIVERSITY (US) | 2024-01-09 | — | — | US | disclosed |
| WO-2023220387-A2 | APOE LIPOPROTEIN SYSTEMS | KISBEE THERAPEUTICS, INC. (US) | 2023-11-16 | — | — | WO | disclosed |
| US-20050282908-A1 | Substituted aminopropoxyaryl derivatives useful as agonists for LXR | SMITHKLINE BEECHAM CORPORATION | 2005-12-22 | — | — | US | disclosed |
| EP-1575495-A2 | COMPOUNDS AND METHODS | SmithKline Beecham Corporation (US) | 2005-09-21 | — | — | EP | disclosed |
| US-20050113580-A1 | Amide compounds and methods of using the same | SMITHKLINE BEECHAM CORP | 2005-05-26 | — | — | US | disclosed |
| EP-1318976-B1 | SUBSTITUTED AMINOPROPOXYARYL DERIVATIVES USEFUL AS AGONISTS FOR LXR | GLAXO GROUP LTD (GB) | 2004-11-24 | — | — | EP | disclosed |
| US-20040072868-A1 | Substitued aminopropoxyaryl derivatives useful as agonists for lxr | SMITHKLINE BEECHAM CORPORATION | 2004-04-15 | — | — | US | disclosed |
| WO-2003082205-A2 | COMPOUNDS AND METHODS | SMITHKLINE BEECHAM CORPORATION (US) | 2003-10-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050282908-A1 | Substituted aminopropoxyaryl derivatives useful as agonists for LXR | NR1H3, NR1H2, NR1H4 | NR1H3 1/4885NR1H2 2/4885RXRA 28/4885 |
| US-20250319190-A1 | APOE LIPOPROTEIN SYSTEMS | APOB, APOL1, LDLR | NR1H3 16/4885NR1H2 18/4885RXRA 1086/4885 |
| US-11865094-B2 | Treatment and diagnosis of melanoma | EYA3, BRAF, CD99 | NR1H3 4400/4885NR1H2 4537/4885RXRA 2268/4885 |
| US-20240252458-A1 | TREATMENT AND DIAGNOSIS OF MELANOMA | EYA3, BRAF, CD99 | NR1H3 4400/4885NR1H2 4537/4885RXRA 2268/4885 |
| US-20050113580-A1 | Amide compounds and methods of using the same | NR1H2, NR1H3, PPARA | NR1H3 2/4885NR1H2 1/4885RXRA 12/4885 |
| US-12502368-B2 | Treatment and diagnosis of melanoma | EYA3, BRAF, CD99 | NR1H3 4400/4885NR1H2 4537/4885RXRA 2268/4885 |
| US-20040072868-A1 | Substitued aminopropoxyaryl derivatives useful as agonists for lxr | NR1H2, NR1H3, NR1H4 | NR1H3 2/4885NR1H2 1/4885RXRA 21/4885 |
| US-10456344-B2 | Hair composition | GLS2, GLS, LHCGR | NR1H3 8/4885NR1H2 6/4885RXRA 2879/4885 |
| US-20170360673-A1 | HAIR COMPOSITION | GLS2, GLS, CYP17A1 | NR1H3 8/4885NR1H2 6/4885RXRA 2917/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.